Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

COVID-19 and Cancer Consortium

研究成果: Article同行評審

12 引文 斯高帕斯(Scopus)

摘要

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non–B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non–recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.

原文English
頁(從 - 到)181-193
頁數13
期刊Blood cancer discovery
3
發行號3
DOIs
出版狀態Published - 2022 5月 1

All Science Journal Classification (ASJC) codes

  • 一般醫學

指紋

深入研究「Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19」主題。共同形成了獨特的指紋。

引用此